Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

News

Rutgers Names David Kimball as VP for Innovation and Research Commercialization of Office of Research and Economic Development

Dr. David Kimball

New Brunswick, NJ, November 25, 2017 — Rutgers University on October 23 announced the appointment of David Kimball, Ph.D., as vice president for innovation and research commercialization of the Office of Research and Economic Development (ORED).

Most recently, Dr. Kimball led translational science and research commercialization as associate vice president in ORED.

“I am delighted to announce David’s promotion to Vice President of Innovation and Research Commercialization,” said Christopher J. Molloy, Ph.D., R.Ph., Senior Vice President for Research and Economic Development at Rutgers University. Continue reading

NJIT’s $21 Million State-of-the-Art Life Sciences and Engineering Center Opens for Innovation

NJIT President Joel Bloom (second from left) and Gov. Chris Christie

Newark, NJ, November 24, 2017 — An array of innovation-focused New Jerseyans – scientists, student researchers, alumni, company executives and elected officials — gathered on campus on September 21 to hail the much-anticipated opening of NJIT’s new Life Sciences and Engineering Center, a $21 million state-of-the-art research facility focused on the future of health care.

Governor Chris Christie helped cut the ribbon on the New Jersey Institute of Technology’s $19 million Life Sciences and Engineering Center, funded by $13.5 million in state Higher Education Capital Facilities grants, including Building Our Future Bond Act (GO Bond) funds. Continue reading

NIH Awards to Test Ways to Store, Access, Share and Compute on Biomedical Data in the Cloud

Bethesda, MD, November 23, 2017 — The National Institutes of Health (NIH) on November 6 announced that 12 awards totaling $9 million in Fiscal Year 2017 will launch an NIH Data Commons Pilot Phase.

A data commons is a shared virtual space where scientists can work with the digital objects of biomedical research, such as data and analytical tools.  The NIH Data Commons will be implemented in a four-year pilot phase to explore the feasibility and best practices for making digital objects available through collaborative platforms.

This will be done on public clouds, which are virtual spaces where service providers make resources, such as applications and storage, available over the internet. Continue reading

Rutgers-Camden’s New Nursing and Science Building’s Labs Offer Greater Learning and Research Opportunities

Camden, NJ, November 22, 2017 — “It’s been a long time coming,” says Danny Bubb, professor and chair of the physics and chemistry departments, as he gives a tour of the cutting-edge science labs in the new Rutgers University–Camden Nursing and Science Building (NSB).

Jeanne Leong reports that in the NSB, located at Fifth and Federal Sts. in Camden, the three new state-of-the-art physics labs provide students and faculty with access to resources including a high-powered microscope, laser systems, and a vibration-free work table only a few other colleges and universities even have.

“These new labs allow us to be very innovative with how we deliver our curriculum to engage students,” says Bubb. Continue reading

Hill Fight Erupts Over GOP’s Proposed Roll-Back of Tax Credit for ‘Orphan’ Disease Drugs

Washington, DC, November 21, 2017 — Peter Sullivan reports in The Hill that Republicans are seeking to roll back a tax credit for drugs that treat rare diseases, alarming patient groups who fear the move would slow the development of new treatments.

The so-called orphan drug tax credit would be repealed in the tax-reform bill that passed the House last week. Patient groups are lobbying to preserve the credit, as are some drug companies.

The credit, first enacted in 1983, is intended to spur the development treatments for rare, or “orphan,” diseases that affect fewer than 200,000 people. Continue reading

Seven Princeton University Researchers Receive NIH BRAIN Initiative Awards

Princeton, NJ, November 21, 2017 — Liz Fuller-Wright reports that  Princeton University projects are among the 121 selected by the National Institutes of Health (NIH) to receive an overall $219 million in funds related to the federal Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative.

Launched in 2013 by the Obama Administration, the BRAIN Initiative is a large-scale effort to push the boundaries of neuroscience research and equip scientists with insights necessary for treating a wide variety of brain disorders such as Alzheimer’s disease, schizophrenia, autism, epilepsy and traumatic brain injury. Continue reading

FDA Announces Comprehensive Regenerative Medicine Policy Framework

Washington, DC, November 20, 2017 — The U.S. Food and Drug Administration (FDA) on November 16 announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework – outlined in a suite of four guidance documents – builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products.

Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. Continue reading

JerseyCAN’s New Report Explores STEM Innovations in NJ and Preparing Today’s Students for Tomorrow’s Jobs

Trenton, NJ, November 19, 2017JerseyCAN last month released a new report, Preparing the Children of Today for the Jobs of Tomorrow: A Window into STEM Education in New Jersey, highlighting STEM innovations across New Jersey.

JerseyCAN met with over 70 individuals and organizations leading pioneering work in STEM education including: superintendents, principals, teachers, students, think tanks, foundations, corporate leaders, scientific institutions, the military, state leaders and academics. Continue reading

NJ Innovation Institute and Rutgers Announce Plans to Form the New Jersey Continuous Manufacturing Institute to Advance Pharmaceutical Industry

Newark, NJ, November 18, 2017 — The New Jersey Innovation Institute (NJII), an NJIT Corporation, and Rutgers University last month announced plans to form the New Jersey Continuous Manufacturing Institute (NJCMI) to advance innovative manufacturing technologies in the pharmaceutical industry.

The NJCMI serves as a center of excellence combining state-of-the-art technologies, infrastructure, facilities and technical expertise to support the development and continuous manufacturing of products for the pharmaceutical industry.

In addition, it provides training, education and workforce development solutions for those who want to expand or gain additional training and expertise in pharmaceutical manufacturing. Continue reading

FDA vs. Pentagon: U.S. House Passes Fix to Defense Bill’s Drug Approval Provision

Washington, DC, November 17, 2017 — Rebecca Kheel reports in The Hill that the U.S. House on Wednesday, November 15 passed by voice vote a bill to speed up Food and Drug Administration (FDA) approval of medical devices and drugs to be used on the battlefield.

The bill is meant to address a controversial provision of the annual defense policy bill passed by the House on Tuesday that would allow the Pentagon to sign off on unapproved devices and drugs.

“Our men and women in uniform have put their lives on the line for this country, and they deserve to have the earliest possible access to medical products that could save their lives on the battlefield,” Energy and Commerce Committee Chairman Greg Walden (R-Ore.) said on the House floor Wednesday. “We found a good balance with our friends on the Armed Services Committee, and in working with the FDA and the leadership of the Pentagon.” Continue reading